Arcellx (ACLX) Stock Plunges as iMMagine-1 Phase 2 Clinical Program Faces Major Setback
Shares of Arcellx, Inc. (NASDAQ: ACLX) took a nosedive in pre-market trading on Tuesday, dropping by a staggering 16.82%. The […]
Arcellx (ACLX) Stock Plunges as iMMagine-1 Phase 2 Clinical Program Faces Major Setback Read More »
